GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...
Kennedy Jr. has his way, get ready for even more anti-pharma rhetoric and potential instability at the Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback